Multi-center, Double Blind, Dose Escalating Study to Compare the Effects of 5 mg, 10mg and 20mg of Desloratadine in Patients With Acquired Cold Urticaria (ACU) (AECUDATT)

NCT01444196 Phase 4 COMPLETED

The primary objective of the study is to assess the dosis of DL which is sufficient to inhibit cold urticaria symptoms.

Details

Lead sponsor	Marcus Maurer
Phase	Phase 4
Status	COMPLETED
Enrolment	30
Start date	2009-08
Completion	2010-05

Conditions

• Urticaria

Interventions

• Desloratadine

Primary outcomes

• CTTs and CSTTs assessed by TEMPtest 3.0 + urticaria network SOPs — 6 weeks

Countries

Germany